December 2, 2024 10:48 AM ESTUpdated 11:00 AM

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

Lei Lei Wu

News Reporter

Novocure announced Monday morning that its electrical fields wearable device combined with chemotherapy passed a late-stage trial in pancreatic cancer, and the biotech now plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sen­ti Bio’s Phase 1 CAR-NK da­ta; Allink rais­es $42M

Novocure says electric field therapy extends life for pancreatic cancer patients by two months

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Merus drug shows ‘unexpected improvement’ in second-line head and neck cancer study

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

Senti Bio’s Phase 1 CAR-NK data; Allink raises $42M